[1]林 潇 陈愉生 李鸿茹.查尔森合并症指数及简化合并症评分对晚期非小细胞肺癌预后的影响[J].福建医药杂志,2020,42(05):23-26.
　LIN Xiao,CHEN Yusheng,LI Hongru.Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2020,42(05):23-26.
点击复制

查尔森合并症指数及简化合并症评分对晚期非小细胞肺癌预后的影响()
分享到：

《福建医药杂志》[ISSN:1002-2600/CN:35-1071/R]

卷:
42
期数:
2020年05期
页码:
23-26
栏目:
临床研究
出版日期:
2020-10-20

文章信息/Info

Title:
Impact of Charlson comorbidity index and simplified comorbidity score on the prognosis of advanced non-small cell lung cancer
文章编号:
1002-2600(2020)05-0023-04
作者:
林 潇 陈愉生1 李鸿茹2
福建医科大学省立临床医学院 福建省立医院老年科(福州 350001)
Author(s):
LIN Xiao;  CHEN Yusheng;  LI Hongru
Department of Geriatric Medicine, Fujian Provincial Hospital, Provincial Clinical Medical College of Fujian Medical University, Fuzhou, Fujian 350001, China
关键词:
非小细胞肺癌;  晚期;  查尔森合并症指数;  简化合并症评分;  预后
Keywords:
non-small cell lung cancer;  advanced;  Charlson comorbidity index;  simplified comorbidity score;  prognosis
分类号:
R734.2
文献标志码:
B
摘要:
目的 探讨查尔森合并症指数(CCI)和简化合并症评分(SCS)对晚期非小细胞肺癌(NSCLC)患者预后的影响。方法 回顾性分析我院收治的398例初治晚期NSCLC患者的临床资料,采用CCI和SCS分别评估患者的合并症情况。应用Kaplan-Meier法分析合并症(CCI、SCS)与预后的关系。结果 398例肺癌患者中,高SCS组(SCS≥9分)有51例,低SCS组(SCS<9分)有347例。高CCI组(CCI≥2分)有31例,低CCI组(CCI<2分)有367例。患者确诊肺癌后中位总生存期为17个月,单因素生存分析提示初始治疗前血清清蛋白(ALB)、SCS与预后有关联,CCI与预后无关联。Cox回归分析提示初始治疗前血清ALB、SCS为影响非小细胞肺癌患者预后的独立因素。结论 SCS能快速、简便地评估晚期NSCLC患者的合并症,是预后的重要影响因素,值得临床推广使用。
Abstract:
Objective To investigate the impact of the Charlson comorbidity index(CCI)and simplified comorbidity score(SCS)on the prognosis of patients with advanced non-small cell lung cancer(NSCLC).Methods The clinical data of 398 patients with newly diagnosed advanced NSCLC admitted to our hospital were retrospectively analyzed.The comorbidities were assessed by CCI and SCS respectively.Kaplan-Meier method was used to analyze the relationship between comorbidities(CCI, SCS)and prognosis of the patients.Results Among the 398 patients with lung cancer, there were 51 cases in the high SCS group(SCS≥9)and 347 cases in the low SCS group(SCS<9).In addition, there were 31 cases in the high CCI group(CCI≥2)and 367 cases in the low CCI group(CCI<2).The median overall survival of the patients after diagnosis of lung cancer was 17 months.Univariate survival analysis suggested that serum albumin(ALB)before initial treatment and SCS were related to prognosis, while CCI was not significantly related to prognosis.Cox regression analysis showed that serum ALB before initial treatment and SCS were independent factors influencing the prognosis of NSCLC patients.Conclusion SCS can evaluate the comorbidities of the patients with advanced NSCLC quickly and easily.It is a key factor influencing the prognosis and is worthy of clinical promotion.

参考文献/References:

[1] Charlson M E, Pompei P, Ales K L, et al.A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J].J Chronic Dis, 1987, 40(5): 373-383.
[2] Colinet B, Jacot W, Bertrandl D, et al.A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the charlsons index[J].British J Cancer, 2005, 93(10): 1098-1105.
[3] Chansky K, Detterbeck F C, Nicholson A G, et al.The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer[J].J Thorac Oncol, 2017, 12(7): 1109-1121.
[4] Singh N, Singh P S, Aggarwal A N, et al.Comorbidity assessment using Charlson comorbidity index and simplified comorbidity score and its association with clinical outcomes during first-line chemotherapy for lung cancer[J].Clin Lung Cancer, 2016, 17(3): 205-213.
[5] Haruki T, Yurugi Y, Wakahara M, et al.Simplified comorbidity score for elderly patients undergoing thoracoscopic surgery for lung cancer[J].Surg Today, 2017, 47(6): 718-725.
[6] Alexander M, Evans S M, Stirling R G, et al.The influence of comorbidity and the simplified comorbidity score on overall survival in non-small cell lung cancer-A prospective cohort study[J].J Thorac Oncol, 2016, 11(5): 748-757.
[7] Jacot W, Colinet B, Bertrand D, et al.Quality of life and comorbidity score as prognostic determinants in non-small-cell lung cancer patients[J].Ann Oncol, 2008, 19(8): 1458-1464.
[8] Lembicz M, Gabryel P, Brajer-Luftmann B, et al.Comorbidity in patients undergoing surgery for lung cancer.Do we have an adequate tool to assess it?[J].Adv Respir Med, 2017, 85(2): 55-63.
[9] Takemura K, Takenaka Y, Ashida N, et al.Age-adjusted Charlson Comorbidity Index predicts prognosis of laryngopharyngeal cancer treated with radiation therapy[J].Acta Otolaryngol, 2017, 137(12): 1307-1312.
[10] Lee S Y, Kang E J, Lee S Y, et al.Efficacy of second-line treatment and importance of comorbidity scores and clinical parameters affecting prognosis in elderly patients with non-small cell lung cancer without epidermal growth factor receptor mutations[J].Oncol Lett, 2018, 15(1): 600-609.
[11] Tanriverdi O, Avci N, Oktay E, et al.Pretreatment serum albumin level is an independent prognostic factor in patients with stage ⅢB non-small cell lung cancer: A study of the Turkish Descriptive Oncological Researches Group[J].Asian Pac J Cancer Prev, 2015, 16(14): 5971-5976.
[12] Lee J H, Wu H G, Kim H J, et al.Influence of comorbidities on the efficacy of radiotherapy with or without chemotherapy in elderly stage Ⅲ non-small cell lung cancer patients[J].Cancer Res Treat,2012, 44(4): 242-250.

相似文献/References:

[1]林清华　吴联平　刘加夫　陈友轩　 齐春能　林玉琼　黄小红　郑　静.晚期非小细胞肺癌患者胸水液基细胞学蜡块中新抗体D5F3检测的临床价值[J].福建医药杂志,2019,41(01):3.
　LIN Qinghua,WU Lianping,LIU Jiafu,et al.Clinical value of D5F3 in hydrothorax fluid based cytological wax block in patients with advanced non-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2019,41(05):3.
[2]陈新富 刘 宁 刘加夫.CK19在非小细胞肺癌淋巴结微转移中的检测价值(附90例分析)[J].福建医药杂志,2020,42(04):6.
　CHEN Xinfu,LIU Ning,LIU Jiafu..Detection value of CK19 in lymph node micrometastasis of NSCLC:analysis of 90 cases[J].FUJIAN MEDICAL JOURNAL,2020,42(05):6.
[3]李荣宾,黄延延,林贤宾,等.IGF1/RPI3K/Akt通路及其调控对非小细胞肺癌血管生成拟态形成影响的研究[J].福建医药杂志,2023,45(03):112.
[4]黄阳,陈静波,林贵山.动态监测循环肿瘤细胞对寡转移非小细胞肺癌联合治疗预后的价值[J].福建医药杂志,2023,45(05):8.
　HUANG Yang,CHEN Jingbo,LIN Guishan.Prognostic value of dynamic monitoring of circulating tumor cells in combination therapy for oligometastaticnon-small cell lung cancer[J].FUJIAN MEDICAL JOURNAL,2023,45(05):8.
[5]钟颖,邹立,陈声池.EGFR T790M突变丰度对阿美替尼治疗晚期非小细胞肺癌疗效的影响[J].福建医药杂志,2024,46(01):17.[doi:10.20148/j.fmj.2024.01.005]
　ZHONG Ying,ZOU Li,CHEN Shengchi.Relationship between abundance of EGFR T790M mutation and efficacy of Almonertinib in the treatment of advanced non-small cell lung cancer patients[J].FUJIAN MEDICAL JOURNAL,2024,46(05):17.[doi:10.20148/j.fmj.2024.01.005]

备注/Memo

备注/Memo:
1 通信作者,Email: cysktz@163.com; 2 呼吸与危重症医学科
更新日期/Last Update: 2020-10-20